 DALLAS--BUSINESS WIRE--Taysha Gene Therapies, Inc. Nasdaq: TSHA, a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations, today announced its support of Rare Disease Day and the launch of its RareAlly initiative to recognize those in the rare disease community who inspire and motivate each other. RareAlly is intended to recognize t 